Occurrence of the JAK2 V617F mutation in the WHO provisional entity: Myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis

Haematologica

Volumn 91, Issue 5, 2006, Pages 719-720

  Remacha, Angel F ^a   Nomdedéu, Josef F ^a   Puget, Guiomar ^a   Estivill, Camino ^a   Sarda, M Pilar ^a   Canals, Carme ^a   Aventin, Anna ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Essential thrombocythemia; JAK2; Polycytheima vera; Sideroblastic anemia; WHO classification

Indexed keywords

JANUS KINASE 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE CLASSIFICATION; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; LABORATORY TEST; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; THROMBOCYTOSIS; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; HUMANS; JANUS KINASE 2; MEGAKARYOCYTES; MUTATION, MISSENSE; MYELODYSPLASTIC SYNDROMES; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; THROMBOCYTOSIS; WORLD HEALTH ORGANIZATION;

EID: 33744478891     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification. Tumours of haematopoietic and lymphoid tissues. IARC press. Lyon 2001.
2. Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 2005;105:22-30.
3. Goerttler PL, Marz E, Johansson PL, Andreasson B, Kutti J, Moliterno AR, et al. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. The MPD Research Consortium. Haematologica 2005;90:851-3.
4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
6. Goerttler PS, Steimle C, Marz E, Johansson PL, Andreasson B, Griesshammer M, et al. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 2005;106:2862-4.
7. Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y, et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005;19:2359-60.
8. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99:1594-601.
9. Shaw GR. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005;131:180-4.
10. Spuzka H, Tiu R, Hsi E, Lichtin AE, Sekeres MA, Theil KS, et al. Presence of JAK2 mutations in MDS-MPD-u WHO classified patients and not other forms of MDS suggests their derivation from classical myeloproliferative syndrome. Blood 2005;106:112a[abstract 369].